Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
Login
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

Resiquimod

Brand and Other Names: Resiquimod
Mechanism of Action:
Indications:
Route:
Dose:
Adverse Reactions:
Contraindication:
Warnings and Precautions:
Description:

Not FDA approved

GOOGLE OVERVIEW

Resiquimod, also known as R-848, is a substance being studied for its potential in treating certain cancers and other conditions. It works by activating immune cells to produce chemicals that can fight tumor cells.Resiquimod is a type of imidazoquinoline and immunomodulator, specifically a TLR7/8 agonist. 
 
Here's a more detailed explanation:
 
Mechanism of Action:
  • Resiquimod stimulates the immune system by activating Toll-like receptors (TLRs) 7 and 8. 
     
  • TLRs are proteins that recognize specific molecules found on pathogens and damaged cells, triggering an immune response. 
     
By activating TLR7/8, resiquimod causes immune cells to produce cytokines, which are signaling molecules that help the immune system fight infections and cancer. 
 
It has been shown to promote the differentiation of myeloid-derived suppressor cells (MDSCs) into macrophages and dendritic cells, potentially enhancing anti-tumor immunity. 
 
Potential Uses:
 
Cancer Treatment:
Resiquimod is being studied for its potential in treating various cancers, including skin cancer. It may be used to enhance the effectiveness of tumor vaccines. 
 
Genital Herpes:
Resiquimod has been investigated for the treatment of genital herpes, but a phase III trial was suspended due to lack of efficacy. 
 
Other Applications:
It has also been explored for its potential in treating other conditions, including cutaneous T-cell lymphoma (CTCL). 
 
Administration and Side Effects:
Resiquimod is often administered topically as a cream.
Common side effects are primarily local and include redness, irritation, and tenderness at the application site.
Side effects usually resolve after discontinuing the drug. 
 
Additional Information:
Resiquimod is a synthetic small molecule. 
 
It is structurally related to imiquimod, another TLR7 agonist. 
 
Resiquimod is available in lyophilized form and should be stored at -20°C, desiccated. 
 
It is also available in solution, which should be stored at -20°C and used within two months to prevent loss of potency
See package insert for full prescribing information.